Precision fermentation startup Vivici, which secured €32.5 million in Series A funding, has now secured an additional €12.5 million from the European Innovation Council Accelerator Programme, according to Greenqueen. This new public funding, equivalent to $14.4 million, boosts Vivici's capital base as it advances its novel dairy protein technologies. The combined private and public investment highlights the significant financial commitment required for scaling alternative protein solutions.

Vivici recently closed a substantial Series A round, but its continued success in securing significant public funding indicates the immense capital requirements and long-term investment horizon for scaling novel food technologies. A dual funding approach suggests a strategic path for companies navigating the complex development cycles of precision fermentation.

Companies in the precision fermentation space will likely continue to rely on a mix of private and public funding to bridge the gap between research and development and widespread market adoption, with regulatory milestones acting as critical valuation drivers. A hybrid model helps mitigate the high costs and extended timelines inherent in bringing new food ingredients to market.

Vivici's Funding Overview